Baseline Detrusor Overactivity Subtype and Impaired Detrusor Contractility Are Associated With Persistent Detrusor Overactivity After β3‐Adrenoceptor Agonist Add‐On Therapy in Men With Lower Urinary Tract Symptoms
International Journal of Urology · 2026
DOI: 10.1111/iju.70654 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yoshihisa Matsukawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Adrenergic beta-3 Receptor Agonists, Lower Urinary Tract Symptoms, Urinary Bladder. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objectives
To identify baseline urodynamic factors associated with persistent detrusor overactivity (DO) after β3‐adrenoceptor agonist add‐on therapy in men with lower urinary tract symptoms (LUTS)/overactive bladder (OAB).
Methods
We retrospectively analyzed 270 men with LUTS/OAB despite ≥ 3 months of α1‐adrenoceptor antagonist or phosphodiesterase type 5 inhibitor monotherapy. All patients had DO on baseline urodynamics and underwent repeat urodynamic evaluation approximately 3 months after add‐on β3‐adrenoceptor agonist therapy. Baseline DO was classified as phasic, terminal, or combined. Patients were categorized into the DO disappearance and persistent DO groups. Baseline urodynamic parameters were compared, and logistic regression analyses were performed.
Results
DO disappeared in 129 patients (47.8%) and persisted in 141 (52.2%). The persistent DO group had significantly lower bladder contractility index (BCI), bladder voiding efficiency (BVE), and bladder outlet obstruction index; the overall DO subtype distribution differed significantly between the groups. In multivariable analysis, with phasic DO as the reference, terminal DO (adjusted odds ratio [OR], 3.08; 95% confidence interval [CI], 1.25–7.59), combined DO (adjusted OR, 4.58; 95% CI, 1.86–11.28), lower BCI (adjusted OR per 10‐unit increase, 0.67; 95% CI, 0.55–0.82), and lower BVE (adjusted OR per 10‐percentage‐point increase, 0.80; 95% CI, 0.66–0.97) were independently associated with persistent DO. The adjusted overall subtype effect was significant ( p = 0.004).
Conclusions
A baseline terminal DO component and impaired detrusor contractility were independently associated with persistent DO after β3‐adrenoceptor agonist add‐on therapy. DO subtype and bladder contractility may help identify a potentially treatment‐resistant urodynamic phenotype in men with LUTS/OAB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Urology, Nihon University School of Medicine, Tokyo, Japan.
- Department of Urology, Aichi Medical University, Nagakute, Aichi, Japan.
- Department of Urology, Kasugai City Hospital, Kasugai, Japan.
ORCID-Profile: Yoshihisa Matsukawa, Tsuyoshi Majima, Shun Takai, Yushi Naito, Tomokazu Kimura, Shohei Ishida
Zitieren
APA
Matsukawa, Y., Majima, T., Takai, S., Naito, Y., Kimura, T., Ishida, S., & Akamatsu, S. (2026). Baseline Detrusor Overactivity Subtype and Impaired Detrusor Contractility Are Associated With Persistent Detrusor Overactivity After β3‐Adrenoceptor Agonist Add‐On Therapy in Men With Lower Urinary Tract Symptoms. International Journal of Urology. https://doi.org/10.1111/iju.70654
Vancouver
Matsukawa Y, Majima T, Takai S, Naito Y, Kimura T, Ishida S, et al. Baseline Detrusor Overactivity Subtype and Impaired Detrusor Contractility Are Associated With Persistent Detrusor Overactivity After β3‐Adrenoceptor Agonist Add‐On Therapy in Men With Lower Urinary Tract Symptoms. International Journal of Urology. 2026. doi:10.1111/iju.70654
BibTeX
@article{Matsukawa2026,
author = {Matsukawa, Yoshihisa and Majima, Tsuyoshi and Takai, Shun and Naito, Yushi and Kimura, Tomokazu and Ishida, Shohei and Akamatsu, Shusuke},
title = {Baseline Detrusor Overactivity Subtype and Impaired Detrusor Contractility Are Associated With Persistent Detrusor Overactivity After β3‐Adrenoceptor Agonist Add‐On Therapy in Men With Lower Urinary Tract Symptoms},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70654}
}
EUVIMED